15/10/2025
🌟 We’re thrilled to announce a groundbreaking partnership between the InnoHK Centre for Immunology & Infection Limited (C2i), its spin-off C2iTech Limited, and Jingke Biotech Group to advance patient-derived organoid (PDO) technologies for personalized oncology solutions! 🎉🔬
Signed by C2i's Managing Director Professor Leo P**n and C2iTech's CEO Professor Michael Chan, this cross-border collaboration, formalized through a Memorandum of Understanding, will launch a Hong Kong-based pilot with local hospitals, focusing on lung cancer to deliver high-quality, reproducible data for PDO-based tumor drug-sensitivity testing. 🩺📊
By leveraging C2i’s GMP-aligned Cell Processing Facility at HKSTP - Hong Kong Science and Technology Parks Corporation and Jingke’s expertise in organoid technology, we’re paving the way for innovative, precision-driven cancer care. 🚀
Our shared vision is to empower clinicians with faster, more confident therapy decisions and to explore how PDOs can address evolving cancer challenges, such as drug resistance and metastasis.
💪 This partnership exemplifies the Greater Bay Area biotech co-innovation, combining cutting-edge R&D, clinical translation, and robust quality systems to transform precision medicine in the region and beyond. 🌍
Read more about this exciting milestone:
https://www.c2i.hk/post/c2i-and-c2itech-join-forces-with-jingke-to-establish-a-cross-border-strategic-partnership-focused-on
C2i is funded by a grant from InnoHK, an initiative of the Innovation and Technology Commission, the Government of the Hong Kong Special Administrative Region.
HKU Medicine The University of Hong Kong 🧬✨
The InnoHK Centre for Immunology & Infection Limited (C2i) and its spin-off C2iTech Limited have signed a Memorandum of Understanding (MOU) with Guangzhou Jingke Biotech Co., Ltd. and Shenzhen Jingke Biotech Co., Ltd. to advance patient-derived organoid (PDO) technologies for personalized oncology.T...
